Answers are grounded in this paper and cite their sources.
Acute and chronic graft-versus-host disease (aGVHD, cGVHD) remain the major clinical complication of allogeneic hematopoietic cell transplantation (HCT) limiting survival and inducing major morbidity, sometimes for several years posttransplant. In this article, 3 authors review components of GVHD that underlie these hazards. Dr. Pavan Reddy outlines preclinical, mostly murine data detailing the current understanding of the pathophysiology of aGVHD. cGVHD, the major ongoing immunologic limitation to transplant success has complexities in its assessment and management, and unfortunately, no defined best therapy.
No takes yet. Share an insight, caveat, or question.
Reddy et al. (2009) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: